These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
254 related articles for article (PubMed ID: 25290340)
1. Cost-effectiveness of HIV drug resistance testing to inform switching to second line antiretroviral therapy in low income settings. Phillips A; Cambiano V; Nakagawa F; Mabugu T; Miners A; Ford D; Pillay D; De Luca A; Lundgren J; Revill P PLoS One; 2014; 9(10):e109148. PubMed ID: 25290340 [TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy. Van Vaerenbergh K Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503 [TBL] [Abstract][Full Text] [Related]
3. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis. Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513 [TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study. Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S; Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084 [TBL] [Abstract][Full Text] [Related]
5. Unnecessary antiretroviral treatment switches and accumulation of HIV resistance mutations; two arguments for viral load monitoring in Africa. Sigaloff KC; Hamers RL; Wallis CL; Kityo C; Siwale M; Ive P; Botes ME; Mandaliya K; Wellington M; Osibogun A; Stevens WS; van Vugt M; de Wit TF; J Acquir Immune Defic Syndr; 2011 Sep; 58(1):23-31. PubMed ID: 21694603 [TBL] [Abstract][Full Text] [Related]
6. Simplifying switch to second-line antiretroviral therapy in sub Saharan Africa: predicted effect of using a single viral load to define efavirenz-based first-line failure. Shroufi A; Van Cutsem G; Cambiano V; Bansi-Matharu L; Duncan K; Murphy RA; Maman D; Phillips A AIDS; 2019 Aug; 33(10):1635-1644. PubMed ID: 31305331 [TBL] [Abstract][Full Text] [Related]
7. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy. Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463 [TBL] [Abstract][Full Text] [Related]
8. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M; Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252 [TBL] [Abstract][Full Text] [Related]
9. How do different eligibility guidelines for antiretroviral therapy affect the cost-effectiveness of routine viral load testing in sub-Saharan Africa? Scott Braithwaite R; Nucifora KA; Toohey C; Kessler J; Uhler LM; Mentor SM; Keebler D; Hallett T AIDS; 2014 Jan; 28 Suppl 1(0 1):S73-83. PubMed ID: 24468949 [TBL] [Abstract][Full Text] [Related]
10. Incidence of switching to second-line antiretroviral therapy and associated factors in children with HIV: an international cohort collaboration. Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration Lancet HIV; 2019 Feb; 6(2):e105-e115. PubMed ID: 30723008 [TBL] [Abstract][Full Text] [Related]
11. Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa. Boender TS; Hoenderboom BM; Sigaloff KC; Hamers RL; Wellington M; Shamu T; Siwale M; Labib Maksimos EE; Nankya I; Kityo CM; Adeyemo TA; Akanmu AS; Mandaliya K; Botes ME; Ondoa P; Rinke de Wit TF Clin Infect Dis; 2015 Dec; 61(11):1749-58. PubMed ID: 26240203 [TBL] [Abstract][Full Text] [Related]
12. The cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software tool. Estill J; Salazar-Vizcaya L; Blaser N; Egger M; Keiser O PLoS One; 2015; 10(3):e0119299. PubMed ID: 25793531 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of different strategies to monitor adults on antiretroviral treatment: a combined analysis of three mathematical models. Keebler D; Revill P; Braithwaite S; Phillips A; Blaser N; Borquez A; Cambiano V; Ciaranello A; Estill J; Gray R; Hill A; Keiser O; Kessler J; Menzies NA; Nucifora KA; Vizcaya LS; Walker S; Welte A; Easterbrook P; Doherty M; Hirnschall G; Hallett TB Lancet Glob Health; 2014 Jan; 2(1):e35-43. PubMed ID: 25104633 [TBL] [Abstract][Full Text] [Related]
14. The REVAMP trial to evaluate HIV resistance testing in sub-Saharan Africa: a case study in clinical trial design in resource limited settings to optimize effectiveness and cost effectiveness estimates. Siedner MJ; Bwana MB; Moosa MS; Paul M; Pillay S; McCluskey S; Aturinda I; Ard K; Muyindike W; Moodley P; Brijkumar J; Rautenberg T; George G; Johnson B; Gandhi RT; Sunpath H; Marconi VC HIV Clin Trials; 2017 Jul; 18(4):149-155. PubMed ID: 28720039 [TBL] [Abstract][Full Text] [Related]
15. Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa. Boender TS; Kityo CM; Boerma RS; Hamers RL; Ondoa P; Wellington M; Siwale M; Nankya I; Kaudha E; Akanmu AS; Botes ME; Steegen K; Calis JC; Rinke de Wit TF; Sigaloff KC J Antimicrob Chemother; 2016 Oct; 71(10):2918-27. PubMed ID: 27342546 [TBL] [Abstract][Full Text] [Related]
16. CD4 count-based failure criteria combined with viral load monitoring may trigger worse switch decisions than viral load monitoring alone. Hoffmann CJ; Maritz J; van Zyl GU Trop Med Int Health; 2016 Feb; 21(2):219-23. PubMed ID: 26584666 [TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa. Phillips AN; Cambiano V; Nakagawa F; Bansi-Matharu L; Sow PS; Ehrenkranz P; Ford D; Mugurungi O; Apollo T; Murungu J; Bangsberg DR; Revill P PLoS One; 2016; 11(12):e0167654. PubMed ID: 27977702 [TBL] [Abstract][Full Text] [Related]
18. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings. Chang LW; Harris J; Humphreys E Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969 [TBL] [Abstract][Full Text] [Related]
19. HIV drug resistance surveillance for prioritizing treatment in resource-limited settings. Walensky RP; Weinstein MC; Yazdanpanah Y; Losina E; Mercincavage LM; Touré S; Divi N; Anglaret X; Goldie SJ; Freedberg KA; AIDS; 2007 May; 21(8):973-82. PubMed ID: 17457091 [TBL] [Abstract][Full Text] [Related]
20. Switching to second-line antiretroviral therapy in resource-limited settings: comparison of programmes with and without viral load monitoring. ; Keiser O; Tweya H; Boulle A; Braitstein P; Schecter M; Brinkhof MW; Dabis F; Tuboi S; Sprinz E; Pujades-Rodriguez M; Calmy A; Kumarasamy N; Nash D; Jahn A; MacPhail P; Lüthy R; Wood R; Egger M AIDS; 2009 Sep; 23(14):1867-74. PubMed ID: 19531928 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]